68 citations
,
September 2003 in “British Journal of Dermatology” Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
September 2023 in “Dermatology and Therapy” Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
1 citations
,
June 2025 in “Cell Biochemistry and Biophysics” 1 citations
,
May 2025 in “Cytotechnology” Icariside II may help treat gastric cancer by stopping tumor growth.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
6 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
March 2026 in “Korean Journal of Clinical Pharmacy” In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
January 2008 in “xPharm: The Comprehensive Pharmacology Reference”
January 2017 in “Brazilian Journal of Pharmaceutical Sciences” Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.
28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
13 citations
,
January 2017 in “Chemical & Pharmaceutical Bulletin” Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.
August 2024 in “JAAD Case Reports” Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
August 2024 in “JEADV Clinical Practice” Mesotherapy with dutasteride improves hair growth and reduces symptoms in frontal fibrosing alopecia.
6 citations
,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
3 citations
,
July 2025 in “International Immunopharmacology” October 2023 in “Journal of cystic fibrosis” 13 citations
,
September 2014 in “BMC Complementary and Alternative Medicine” Tanshinone IIA helps protect skin tissue from low oxygen damage by boosting certain cell markers.
9 citations
,
April 2006 in “International Journal of Dermatology” DFMO may help control hair growth and treat cancer.
1 citations
,
January 2012 in “Zhongguo shiyan fangjixue zazhi” Kang'ai injection with FLO chemotherapy improves effectiveness and quality of life in advanced gastric cancer patients.
February 2026 in “JAAD International” 3 citations
,
December 2000 in “PubMed” CS-891 may effectively treat hair loss by blocking enzymes in hair follicles.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
68 citations
,
January 2014 in “Dermatology research and practice” Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.